Arizona just opened a state-level liability lane on hair-relaxer cancer — and L'Oréal's €44B group is the test case

Arizona Attorney General Kris Mayes filed a consumer-fraud action in Maricopa County Superior Court on Thursday, September 10, 2026, making Arizona the first US state to sue over alleged cancer risks in chemical hair relaxers. The complaint names L'Oréal USA, Inc., L'Oréal USA Products, Inc., L'Oréal S.A., and SoftSheen-Carson LLC, and the brands on the products list — Dark & Lovely, Optimum, Mizani, Bantu, Care Free Curl, Look of Radiance, Roots of Nature, and Ultra Precise — are all L'Oréal-owned. The state is asking for injunctive relief requiring warnings, maximum statutory civil penalties per willful violation, restitution, and attorneys' fees.

After acquiring Soft Sheen in 1998 and Carson in 2000, L'Oréal ended up controlling roughly half of US retail women's hair relaxer kit sales, with three of the top five selling brands — a position the Department of Antitrust memorialized in its 2000 competitive-impact statement. That dominance is what makes the company's €16.1B Consumer Products division (FY2025 sales, +3.5% like-for-like) the largest single concentration of plaintiff harm in MDL 3060. The market is small in dollars but enormous in legal gravity: industry sizing puts the US chemical relaxer category at roughly $718 million of annual sales.

Even at 32x trailing earnings and a €202B market capitalization, L'Oréal's $44B revenue base absorbs a federal MDL settlement that would be catastrophic for a smaller defendant. What changes the math now is the consumer-fraud theory: Arizona is not asking a jury to credit one study — it is asking whether the company had \"actual knowledge\" of the underlying studies and chose silence. That pleading architecture is replicable across states.

Arizona's lawyers at DiCello Levitt built the complaint around four epidemiological studies, each of which has survived peer review and is already part of the federal MDL record. The Chang analysis of 33,497 women in the NIH Sister Study found frequent straightener users face a roughly doubled uterine cancer risk; the Bertrand Black Women's Health Study found a 60% higher uterine cancer risk among relaxer users, rising to 71% with 20+ years of use; and a 2025 Bailey analysis of the same Sister Study cohort added a 71% increased thyroid cancer risk and a 166% increased pancreatic cancer risk for frequent users. Arizona's pleading cites these figures in alleging the defendants \"had actual knowledge\" of the underlying studies.

In the Northern District of Illinois, Judge Mary Rowland's MDL 3060 now lists 12,129 plaintiffs — a number that climbed through 2025 as new filings outpaced settlements. The bellwether pool has been narrowed from ten cases to five, discovery against second-wave defendants runs through July 15, 2027, and the first federal trial is set for January 2027. No plaintiff has yet received a settlement payout through the MDL, and mass-tort attorneys are framing individual claim values at $150,000 to $750,000 per uterine cancer case.

Beyond L'Oréal, the named MDL 3060 defendants include SoftSheen-Carson, Revlon, Strength of Nature, Godrej Consumer Products, Namaste Laboratories, Avlon Industries, House of Cheatham, Advanced Beauty, Wella Operations US, and Murrays Worldwide. Of these, only Godrej Consumer Products is publicly listed with material hair relaxer exposure; Wella is owned by KKR and filed for a US IPO on August 31, 2026; Revlon trades only OTC after a 2022 bankruptcy that remains a structural obstacle to recovery in this MDL.

The EU's Commission Regulation 2026/909, adopted April 27, 2026, restricts or prohibits 12 substances — including formaldehyde releasers and several phthalates — under the Cosmetics Regulation, with new compliance from January 1, 2027 and a market-cleanup date of August 1, 2028. Across the Atlantic, the FDA missed its January 2026 statutory deadline to propose a ban on formaldehyde and formaldehyde-releasers in hair straightening products. The asymmetry matters because the EU already forces a reformulation path, while the US litigation clock keeps running on the old chemistry.

Stripped of litigation noise, L'Oréal trades at roughly 4.5x EV/sales and 32x trailing earnings on FY2025 net profit of €6.13B — a premium that reflects the Consumer Products division's recurring revenue and the Professional Products division's 22.9% operating margin. Estée Lauder sits at 2.7x EV/sales but at a heavily distorted 192x trailing P/E because of FY2026 EPS compression; Coty trades at less than 1x sales on negative trailing earnings; Godrej Consumer Products trades on its domestic India multiple without a clean peer comparable for litigation pricing. None of these multiples currently embed a quantified US state-AG settlement scenario.

If the MDL bellwether in January 2027 produces a single adverse verdict at the upper end of the $750,000 per-claim range and Arizona secures the injunction it is asking for, the implied reserve on L'Oréal's books would still represent a fraction of its €6.13B FY2025 net profit — but the disclosure would mark the moment peer multiples reprice. The Arizona suit is the trigger that makes that mark-to-market explicit.

Short-term (days–quarters): the Arizona response, any second state-filing within 30 days (California AG offices have been briefed on the federal MDL since 2023), L'Oréal's next quarterly contingency disclosure, and the Wella IPO roadshow — which will put a price on MDL 3060 exposure that the private market has never had to mark.

Long-term (1–3 years): the January 2027 bellwether verdict, the EU's August 2028 cleanup deadline for non-compliant formulas, and the FDA's pending formaldehyde rule. Watch for Godrej Consumer Products to either settle out or seek dismissal like Dabur did in November 2023 — and watch Coty to disclose any indemnification tail from its Wella carve-out agreements.

Arizona's complaint frames this as a consumer-fraud story, but the underlying exposure is a beauty-supply-chain story: a single chemistry class (hydroxide relaxers plus phthalate/parabens additives) underlies L'Oréal's largest US ethnic-haircare franchise, Godrej Consumer Products's Just For Me line, the soon-to-be-public Wella portfolio, and a thin shelf of private-label defendants. Investors pricing the next twelve months should treat the Arizona filing not as an L'Oréal-only headline but as the first state in what is now an enforcement queue — and a tell that the same chemistry will be repriced across every name that touches it.